

Dental health of CCS

1 **Dental health of childhood cancer survivors – a report from the Swiss Childhood**

2 **Cancer Survivor Study (SCCSS)**

3 Nigg C¹, Matti C¹, Jörger P^{1,2}, von Bueren AO³, Filippi C⁴, Diesch-Furlanetto T⁵,

4 Tomášiková, Z⁶, Kuehni CE^{1,7}, Sommer G¹

5 ¹ *Institute of Social and Preventive Medicine, University of Bern, Switzerland*

6 ² *Graduate School for Health Sciences, University of Bern, Switzerland*

7 ³ *Department of Paediatrics, Obstetrics and Gynaecology, Division of Paediatric*

8 *Haematology and Oncology, University Hospital of Geneva, Switzerland*

9 ⁴ *Department of Children and Adolescent Dentistry, University Center for Dental Medicine*

10 *Basel (UZB), Basel, Switzerland*

11 ⁵ *Department of Oncology/Haematology, Basel, University Children's Hospital Basel UKBB,*

12 *Basel, Switzerland*

13 ⁶ *Childhood Cancer Switzerland*

14 ⁷ *Division of Pediatric Hematology/Oncology, Inselspital, Bern University Hospital,*

15 *University of Bern, Bern, Switzerland*

16 Correspondence: Prof. Claudia E. Kuehni, Institute of Social and Preventive Medicine,
17 University of Bern, Mittelstrasse 43, 3012 Bern, Switzerland; phone: +41 31 684 35 07,
18 e-mail: claudia.kuehni@unibe.ch

19

20 Word count abstract: 249

21 Word count main text: 2,826

22 Number of tables: 4; number of figures: 1; number of supporting information files: 1

23

24 *Keywords:* pediatric oncology, survivorship, late effects, dental care, cohort study, late effects

25

Dental health of CCS

26 **Abstract**

27 **Background:** Cancer and its treatments can affect dental health of childhood cancer
28 survivors. We aimed to evaluate prevalence of dental problems in survivors, compare them to
29 their siblings, and investigate cancer-related risk factors.

30 **Methods:** As part of the population-based Swiss Childhood Cancer Survivors Study, we sent
31 questionnaires inquiring about dental problems to survivors aged 5-19 years and their
32 siblings. We retrieved cancer-relevant information from the Swiss Childhood Cancer
33 Registry and used logistic regressions to compare dental problems between survivors and
34 siblings and to investigate cancer-related risk factors.

35 **Results:** We included 735 survivors and 144 siblings. Almost half of survivors and siblings
36 reported at least one dental problem. Compared to siblings, survivors had a greater risk for
37 hypo- or microdontia (OR 1.7; 95%CI 0.9-3.2) and enamel hypoplasia (2.2; 0.8-6.0), but
38 similar risk for cavities or cavity-related tooth loss (0.8; 0.6-1.3). Chemotherapy was
39 associated with enamel hypoplasia (3.0; 1.2-10.4), cavities or cavity-related tooth loss (1.5;
40 1.0-2.3), and gum problems during (23.0; 9.4-76.2) and after (4.6; 2.0-13.5) treatment.
41 Hematopoietic stem cell transplantation (HSCT) was related to hypo- or microdontia (5.4;
42 2.6-10.7), cavities or cavity-related tooth loss (2.1; 1.2-3.6), and gum problems during
43 treatment (2.0; 1.2-3.6). For hypo- or microdontia and cavities, associations with treatment
44 were driven by patients diagnosed <5 years.

45 **Conclusion:** Childhood cancer patients treated with chemotherapy or HSCT, especially at a
46 young age, were at higher risk for dental problems. Regular dental check-ups guided by
47 healthcare teams and dental hygiene habits can mitigate risks and promote survivor's long-
48 term dental health.

49

50 **Introduction**

51 Medical advancements allow to cure most children diagnosed with cancer, with 5-year
52 survival rates approaching 90% in Switzerland.¹ Despite those advancements, two thirds of
53 survivors develop somatic late effects of cancer treatments that may include a broad range of
54 health problems.²⁻⁷ Some late effects are already visible shortly after treatment, including
55 dental problems.⁸ Early childhood is a crucial phase for crown and root formation,⁹ making
56 patients treated with radiation to the head, chemotherapy, or hematopoietic stem cell
57 transplantation (HSCT) particularly susceptible for dental late effects. Radiation to the head
58 and neck area can cause salivary gland hypofunction, resulting in xerostomia and increased
59 caries,^{10,11} or damage the tooth bud, disrupting tooth development and leading to structural
60 anomalies, such as enamel hypoplasia, microdontia, or hypodontia.¹² Chemotherapy,
61 especially alkylating agents, interfere with the cell cycle and the intracellular metabolism,
62 altering odontoblast and ameloblast activity.^{11,13} Recipients of HSCT may experience salivary
63 gland hypofunction as a result of conditioning regimes or as an early symptom of chronic
64 graft-versus-host disease.^{11,14,15}

65 Two previous meta-analyses including children treated with chemotherapy or a
66 combination of chemotherapy and radiotherapy indicate an increased risk for tooth agenesis
67 and microdontia, enamel hypoplasia, cavities, and gingivitis.^{8,16} While most of the studies
68 included used dental examinations, they were restricted to patients receiving specific
69 treatment regimes, or small populations. The few population-based or cohort studies on
70 dental health come from North America and only include adult participants^{12,17}, who were
71 already in their thirties or forties at time of study. We aimed to evaluate dental health in a
72 population-based study of young childhood cancer survivors (CCS) in Switzerland, a country
73 with different dental hygiene practices and eating habits than North America.^{18,19} In
74 particular, this study evaluated prevalence of dental problems in pediatric CCS, compared it

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

Dental health of CCS

75 with their siblings, and investigated cancer-related factors contributing to dental problems in
76 pediatric CCS.

77

78 **Methods**

79 *Study design and study population*

80 The Swiss Childhood Cancer Survivor Study (SCCSS) is a population-based study nested in
81 the Swiss Childhood Cancer Registry (ChCR). Detailed methods of the SCCSS are available
82 elsewhere.²⁰ The ChCR includes all children and adolescents diagnosed with leukemias,
83 lymphomas, central nervous system (CNS) tumors, malignant solid tumors, or Langerhans
84 cell histiocytosis prior to age of 20 years in Switzerland since 1976.²¹ As part of the SCCSS,
85 we sent questionnaires to CCS who had survived ≥ 5 years since their initial diagnosis.

86 Questionnaires are available in German, French, and Italian language. For this study, we
87 included CCS who participated in the SCCSS between 2015 and 2022, were aged between 5
88 and 19 years at the time of study, and consented to participate. For CCS aged between 5 and
89 15 years, we asked their parents to fill-in the questionnaire. Siblings of similar age (5-19
90 years) received the same questionnaire between 2022 and 2024 without cancer-related
91 questions. Ethical approval was granted by the ethics committee of the canton of Bern,
92 Switzerland (KEK-BE: 166/2014 and 2021-01462).

93

94 *Dental health*

95 The questionnaire asked CCS and siblings about experiencing hypodontia, microdontia,
96 enamel hypoplasia, cavities, and tooth loss due to cavities and gum disease. It asked CCS, but
97 not siblings, if they experienced gum problems during or after cancer treatment, and if they
98 had problems with health insurance coverage for any dental problems. Participants could
99 report on other dental problems qualitatively in a comment field. For a detailed overview of

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

Dental health of CCS

100 the questions, please see *Supplementary Table 1*. For questions in the original language,
101 please contact the authors.

102

103 *Explanatory variables*

104 *Sociodemographic characteristics.* We assessed the following sociodemographic
105 characteristics via questionnaires: Swiss language region, sibling status, parental and
106 participant nationality, and parental education. We categorized the language region into
107 German and French/Italian. We divided CCS' sibling status into yes (≥ 1 sibling) and no (0
108 siblings). We used the nationality to define migration background. For migration background
109 and parental education, we applied definitions of the Federal Statistics Office.^{22,23} If both
110 parents were born Swiss or if the participant and at least one parent were born Swiss, we
111 defined this as no migration background.²² We considered the highest educational degree
112 obtained by either parent, which we divided into three categories: primary education
113 (compulsory schooling only), secondary education (higher schooling and vocational training),
114 or tertiary education (upper vocational education, university or technical college).²³ We
115 received date of birth and sex of the CCS from the ChCR and of the siblings from
116 questionnaires.

117 *Cancer-related characteristics.* We received the following cancer-related
118 characteristics from the ChCR: age at diagnosis, diagnosis according to the International
119 Classification of Childhood Cancer, third edition (ICCC-3)²⁴ and Langerhans Cell
120 Histiocytosis. Treatment information included chemotherapy, radiotherapy, cranial radiation,
121 including radiation to the head, neck or total body irradiation with any dose, HSCT, and
122 relapse (all yes/no).

123

124

Dental health of CCS

125 *Statistical analysis*

126 We first weighted siblings using inverse probability weighting to be representative of CCS
127 with regards to sex, age, migration, and language region as described previously.^{6,25}
128 Secondly, we calculated number and proportion of CCS and their siblings who reported at
129 least one dental problem, as well as for each specific dental problem individually. Third, we
130 used multivariable logistic regression analysis to compare the odds for dental problems
131 between CCS and siblings. For this analysis, we combined hypo- and microdontia into one
132 outcome and cavities and cavity-related tooth loss a second one. We considered adjusting for
133 family clustering via multilevel modeling. Since one-level models yielded similar results, we
134 decided for one-level models due to model parsimony. We computed separate multivariable
135 logistic regression models for each dental problem, deciding *a priori* to include participant
136 type (CCS/sibling), age at study, and sex as predictors. Fourth, to investigate cancer-related
137 risk factors for each dental problem, we applied multivariable logistic regression analysis
138 using data from CCS. We decided *a priori* to include chemotherapy, cranial radiation, HSCT,
139 age at diagnosis, age at study, time since diagnosis, and relapse in all models, but dropped
140 age at study due to multicollinearity. Since early childhood is a crucial dentition phase, we
141 ran age-stratified analysis (diagnosis <5 years / ≥5 years) for prevalence of dental problems
142 and investigation of cancer-related risk factors.¹¹

143 We included all participants responding to at least one dental health question
144 (complete-case analysis). In sensitivity analyses, we imputed missing values using the
145 Multivariate Imputation via Chained Equations (MICE) package²⁶ to specify an imputation
146 model with the algorithm iteratively imputing multiple possible values for missing values.
147 We ran imputations separately for models comparing CCS and siblings, and for models
148 investigating cancer-related risk factors in CCS. We generated 20 datasets with 20 iterations
149 and pooled results based upon Rubin's rule.²⁷

Dental health of CCS

150 **Results**

151 In total, of 1597 families with eligible CCS, 1339 were contacted with a questionnaire. Of
152 those, 763 (57%) returned the questionnaire and 735 (55%) responded to at least one question
153 about dental problems. Of 451 families with eligible siblings, 438 were contacted. Of those,
154 144 responded to at least one question about dental problems (33%). *Supplementary Figure 1*
155 shows the study population flow chart with details on reasons for not contacting or exclusion
156 of CCS and siblings. Median age at study was 12.8 years (interquartile range [IQR] 10.2-
157 15.2) for CCS and 13.5 years (IQR 11.1-15.5) for siblings. For CCS, median age at diagnosis
158 was 4.2 years (IQR 2.1-7.2), and median time since diagnosis 8.2 years (IQR 6.9-9.4).
159 Leukemia was the most common cancer diagnosis (41%), followed by CNS tumors (17%)
160 and lymphomas (8%). Eighty percent of CCS had received chemotherapy treatment, 9%
161 cranial radiotherapy, and 9% HSCT (see *Table 1*).

162

163 *Prevalence of dental problems in CCS and comparison with siblings*

164 CCS and siblings reported having at least one dental problem with similar frequency, but the
165 type of dental problems differed (*Figure 1* and *Supplementary Table 2*). Eight percent of CCS
166 reported having hypodontia (95% confidence interval (CI) 6-10), 11% microdontia (95% CI
167 8-13), and 8% (95% CI 6-10) enamel hypoplasia. Cavities were prevalent in 39% of CCS
168 (95% CI 35-43) and tooth loss due to cavities or gum disease in 6% (95% CI 4-7). Thirty-four
169 percent (95% CI 30-37) of CCS reported gum problems during treatment, and 14% (95% CI
170 11-17) after treatment. When we stratified the analysis by age of diagnosis, we found that
171 compared to cancer patients diagnosed at 5 years or older, cancer patients diagnosed before
172 the age of 5 years had higher prevalence of hypodontia (10% vs. 4%) and microdontia (14%
173 vs. 5%). Gum problems during treatment were more prevalent in cancer patients diagnosed at
174 5 years or older (39%) compared to those diagnosed before the age of 5 years (30%)

Dental health of CCS

175 (*Supplementary Table 3*). For an overview of prevalence rates in siblings without survey
176 weights and dental problems reported in open questions, see *Supplementary Table 4*.

177 After controlling for age and sex, we found a trend towards an increased risk for
178 hypo- or microdontia (OR=1.70, 95% CI 0.89-3.24) and enamel hypoplasia (OR=2.23, 95%
179 CI 0.83-5.96) in CCS compared to siblings. Cavities and tooth loss were similar between
180 CCS and siblings (OR=0.84, 95% CI 0.56-1.28) (see *Table 2*).

181 Of all CCS reporting at least one dental problem (N = 329), 20% reported problems
182 with health care insurance covering associated costs. Insurance problems varied by dental
183 problem (see *Supplementary Table 5*).

184

185 *Cancer-related risk factors of dental problems in CCS*

186 After controlling for age at diagnosis, time since diagnosis, and relapse, chemotherapy
187 treatment was consistently associated with dental problems. This included enamel hypoplasia
188 (OR=3.08, 95% CI 1.22-10.40), cavities or cavity-related tooth loss (OR=1.52, 95% CI 1.01-
189 2.31) as well as gum problems during (OR=22.97, 95% CI 9.37-76.23) and after cancer
190 treatment (OR=4.62, 95% CI 1.98-13.49). We found similar associations between HSCT and
191 dental problems. Specifically, cancer patients who underwent HSCT had an increased risk for
192 hypo- or microdontia (OR = 5.37, 95%CI 2.64-10.69), cavities or cavity-related tooth loss
193 (OR = 2.10, 95%CI 1.24-3.57), and gum problems during treatment (OR = 2.03, 95%CI 1.16-
194 3.60) compared to CCS without HSCT. Cranial radiation was unrelated to all dental problems
195 (see *Table 3*).

196 Age stratified analyses showed that associations between cancer-related risk factors
197 and dental problems differed by age group (see *Table 4*). Cancer patients diagnosed before
198 the age of 5 years had an increased risk for hypo- or microdontia when treated with
199 chemotherapy (OR=5.89, 95% CI 2.08-24.80) or HSCT (OR=2.76, 95% CI 1.34-5.58). They

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

Dental health of CCS

200 were also at higher risk for cavities or cavity-related tooth loss when treated with HSCT
201 (OR=3.25, 95% CI 1.64-6.59). We did not observe those associations in cancer patients
202 diagnosed at the age of 5 years or older. All other treatment-related risk factors were similarly
203 related to dental problems across age diagnosis groups.

204

205 *Sensitivity analysis*

206 In imputed data analysis, we included $N = 907$ study participants ($N = 763$ CCS, $N = 144$
207 siblings). Analyses yielded the same conclusions as complete-case analysis; in fact, most
208 associations became stronger and confidence intervals smaller (see *Supplementary Table 6*
209 and *Supplementary Table 7*).

210

211 **Discussion**

212 This national survey in Switzerland found that CCS were at higher risk for hypo- or
213 microdontia and enamel hypoplasia than their siblings, while cavities and cavity-related tooth
214 loss did not differ between CCS and siblings. Chemotherapy and HSCT were consistently
215 related to dental problems. Cancer patients diagnosed before the age of 5 and treated with
216 chemotherapy or HSCT were particularly susceptible to hypo- or microdontia, as well as
217 cavities or cavity-related tooth loss.

218 The most prevalent dental problem in CCS was cavities. It is difficult to compare
219 prevalence rates for cavities and cavity-related tooth loss to other studies with pediatric CCS
220 since those studies used the composite Decayed, Missing, Filled Teeth (DMFT) score
221 obtained through dental examinations.^{8,28} Existing population-based or cohort studies using
222 questionnaires with adult CCS showed that similar to our study, cavities were the most
223 prevalent problem across all dental problems investigated.^{12,17} While in our study, prevalence
224 was 8% for hypodontia and 11% for each microdontia and enamel hypoplasia, other studies

Dental health of CCS

225 with CCS of similar age indicate higher prevalence for microdontia (16-31%), hypodontia
226 (11-36%), and enamel hypoplasia (12-32%).^{16,28-31} These differences are likely due to those
227 studies assessing dental problem using dental examinations and clinical methods such as
228 radiographic imaging. When comparing to CCS questionnaire studies in adults, prevalence
229 rates were similar for microdontia (9-14%), hypodontia (8-10%), and enamel hypoplasia (12-
230 17%).^{12,17} Higher prevalence of hypo- and microdontia in CCS diagnosed in early childhood
231 was in line with previous findings,^{29,30} and mirrors young children's susceptibility to dental
232 late effects of cancer treatment due to being in a crucial dentition phase.⁹

233 In line with our results, studies from clinical examination in pediatric CCS¹⁶ and in
234 population-based or cohort questionnaire studies with adult CCS^{12,17} found a higher risk for
235 hypo- or microdontia and enamel hypoplasia in CCS than in controls. Population-based and
236 cohort questionnaire studies with adult CCS also showed that cavity risk is similar in CCS
237 and siblings.^{12,17} Similar cavity risk could be due to increased awareness regarding the
238 importance of dental care during cancer treatment, with clinical practitioners taking
239 preventive measures against cavity-related risk factors induced by cancer treatment, such as
240 xerostomia. Another potential explanation is the strong impact of diet and dental hygiene on
241 cavities,^{32,33} which is likely similar within families (i.e., CCS and the sibling control group),
242 masking the impact of cancer treatment on dental health.

243 Among cancer-related risk factors, chemotherapy was linked to higher risks of enamel
244 hypoplasia, cavities or tooth loss due to cavities, and gum problems both during and after
245 treatment. Previous studies utilizing clinical examinations have reported comparable findings
246 regarding the effects of chemotherapy.⁸ HSCT was associated with increased risks of hypo-
247 or microdontia, cavities or tooth loss due to cavities, and gum problems during treatment Our
248 results are similar to findings from a review summarizing results of ten studies that CCS who
249 underwent HSCT had an increased risk for micro- and hypodontia, while findings regarding

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

Dental health of CCS

250 the impact of HSCT on cavities are conflicting.³⁴ We found that the risk for dental problems
251 was high when chemotherapy or HSCT was administered at or before the age of 5 years. This
252 demonstrates the profound impact of cancer treatment on dentition in the early years when
253 crown and root formation are occurring.¹¹ Cranial radiation was unrelated to all dental
254 problems in both overall and age-stratified analysis, which contrasts previous findings.^{10,11}
255 There are several potential explanations for this finding. The radiation location in the head or
256 neck-area may not have involved the salivary glands or tooth buds, or the radiation dose
257 could have been too low to cause damage. In Switzerland, proton instead of photon
258 radiotherapy has been increasingly used, which may cause fewer dental problems.³⁵⁻³⁷ Further
259 investigations into the underlying reasons are necessary.

260 With one out of five survivors reporting issues with health insurance coverage for
261 dental problems, our study implies that assessing dental health before cancer treatment is
262 crucial to secure insurance coverage for potential post-treatment dental problems in
263 healthcare systems where health insurance covers dental costs only if they are a sequelae of a
264 disease (such as in Switzerland). Healthcare providers are essential to support survivors and
265 their parents in obtaining health insurance coverage and to help CCS monitoring and
266 maintaining dental health. This includes encouraging annual dental check-ups following
267 COG guidelines¹¹ to treat potential conditions and avoid further damage regarding
268 development of the jaw and other teeth resulting from those conditions. Fostering dental
269 hygiene habits such as brushing, flossing, and maintaining a low-sugar diet can further reduce
270 the risk of cavities. Supporting older children and adolescent survivors of childhood cancers
271 in avoiding behaviors like smoking and excessive alcohol consumption can also contribute to
272 better long-term dental health.^{38,39}

273 Our population-based, representative study adds evidence to the field of dental late
274 effects by providing results from pediatric CCS between 5-19 years, reducing recall bias,

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

Dental health of CCS

275 providing insights into dental problems of CCS outside North America, and comparing the
276 results to a control group having a similar context as CCS. Previous studies covered only
277 adult CCS or were clinical studies with smaller and selective pediatric populations. We
278 combined patient-reported information with systematically coded clinical information from
279 the ChCR. Our study uses self-reported information about dental problems, which may lead
280 to underestimation of dental late effects. The relatively small number of siblings in the
281 control group may have introduced selection bias. Although we had a large cohort, some
282 dental problems were rare, leading to limited statistical power and bearing the risk that we
283 may have missed associations when comparing the risk for dental problems between CCS
284 and siblings. When we imputed missing data, the associations became stronger and
285 confidence intervals smaller, strengthening confidence in our conclusions. Finally, we did not
286 have detailed treatment information, such as the use of alkylating agents or dental status at
287 the time of treatment, which can modify the effect of cancer-treatment on dental late effects.¹¹

288 In conclusion, we found that child and adolescent survivors of childhood cancer have
289 an increased risk for hypodontia, microdontia, and enamel hypoplasia compared to their
290 siblings. Healthcare providers should be aware of the increased risk of dental problems
291 among child and adolescent survivors of childhood cancers, especially if patients were treated
292 with chemotherapy or HSCT before the age of five years.

293

294 **Conflict of Interest statement**

295 We have no conflict of interests to declare.

296

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

Dental health of CCS

297 **Acknowledgements**

298 We thank all survivors for participating in our study, the study team of the Childhood Cancer
299 Research Group, the data managers of the Swiss Paediatric Oncology Group, and the team of
300 the Swiss Childhood Cancer Registry.

301

302 **Funding**

303 This study was financially supported by the Swiss Cancer League and Swiss Cancer Research
304 (KLS/KFS-482501-2019, KLS/KFS-5711-01-2022), Kinderkrebshilfe Schweiz
305 (www.kinderkrebshilfe.ch), Kinderkrebs Schweiz (www.kinderkrebs-schweiz.ch) and
306 Stiftung für krebskranke Kinder - Regio Basiliensis (<https://www.stiftung-kinderkrebs.ch>).

307

308 **Data availability statement**

309 The data that support the information of this manuscript were accessed on secured servers of
310 the Institute of Social and Preventive Medicine at the University of Bern. Individual-level,
311 fully anonymized, sensitive data can only be made available for researchers who fulfil the
312 respective legal requirements. Requests of data from the Childhood Cancer Registry must be
313 directed to the Childhood Cancer Registry of Switzerland
314 (<https://www.childhoodcancerregistry.ch>). Requests of data from the Swiss Childhood
315 Cancer Survivor Study (SCCSS) should be communicated to the study lead Claudia E.
316 Kuehni (claudia.kuehni@unibe.ch).

317

318

319 **References**

- 320 1. Schindler M, Belle FN, Grotzer MA, Von Der Weid NX, Kuehni CE. Childhood cancer
321 survival in Switzerland (1976–2013): Time trends and predictors. *Int J Cancer*.
322 2017;140(1):62-74. doi:10.1002/ijc.30434
- 323 2. Bhakta N, Liu Q, Ness KK, et al. The cumulative burden of surviving childhood cancer: an
324 initial report from the St Jude Lifetime Cohort Study (SJLIFE). *Lancet*. 2017;390(10112):2569-
325 2582. doi:10.1016/s0140-6736(17)31610-0
- 326 3. Hammoud RA, Liu Q, Dixon SB, et al. The burden of cardiovascular disease and risk for
327 subsequent major adverse cardiovascular events in survivors of childhood cancer: a
328 prospective, longitudinal analysis from the St Jude Lifetime Cohort Study. *Lancet Oncol*.
329 2024;25(6):811-822. doi:10.1016/s1470-2045(24)00157-8
- 330 4. Christen S, Roser K, Mader L, et al. Incidence and prevalence of musculoskeletal health
331 conditions in survivors of childhood and adolescent cancers: A report from the Swiss childhood
332 cancer survivor study. *Cancer Medicine*. 2024;13(8):e7204. doi:10.1002/cam4.7204
- 333 5. Weiss A, Sommer G, Kasteler R, et al. Long-term auditory complications after childhood
334 cancer: A report from the Swiss Childhood Cancer Survivor Study. *Pediatr Blood Cancer*.
335 2017;64(2):364-373. doi:10.1002/pbc.26212
- 336 6. Kasteler R, Weiss A, Schindler M, et al. Long term pulmonary disease among Swiss
337 childhood cancer survivors. *Pediatr Blood Cancer*. 2018;65(1):e26749. doi:10.1002/pbc.26749
- 338 7. Whelan KF, Stratton K, Kawashima T, et al. Ocular late effects in childhood and adolescent
339 cancer survivors: A report from the childhood cancer survivor study. *Pediatr Blood Cancer*.
340 2010;54(1):103-109. doi:10.1002/pbc.22277
- 341 8. Busenhardt DM, Erb J, Rigakos G, Eliades T, Papageorgiou SN. Adverse effects of
342 chemotherapy on the teeth and surrounding tissues of children with cancer: A systematic
343 review with meta-analysis. *Oral Oncol*. 2018;83:64-72.
344 doi:10.1016/j.oraloncology.2018.06.001
- 345 9. Smith BH. Standards of human tooth formation and dental age assessment. Wiley-Liss Inc.;
346 1991.

Dental health of CCS

- 347 10. Milgrom SA, van Luijk P, Pino R, et al. Salivary and Dental Complications in Childhood
348 Cancer Survivors Treated With Radiation Therapy to the Head and Neck: A PENTEC
349 Comprehensive Review. *Int J Radiat Oncol Biol Phys*. 2024;119(2):467-481.
350 doi:10.1016/j.ijrobp.2021.04.023
- 351 11. Effinger KE, Migliorati CA, Hudson MM, et al. Oral and dental late effects in survivors of
352 childhood cancer: a Children's Oncology Group report. *Support Care Cancer*.
353 2014;22(7):2009-2019. doi:10.1007/s00520-014-2260-x
- 354 12. Kaste SC, Goodman P, Leisenring W, et al. Impact of radiation and chemotherapy on risk of
355 dental abnormalities. *Cancer*. 2009;115(24):5817-5827. doi:10.1002/cncr.24670
- 356 13. Kaste SC, Hopkins KP, Jenkins JJI. Abnormal odontogenesis in children treated with radiation
357 and chemotherapy: imaging findings. *Am J Roentgenol*. 1994;162(6):1407-1411.
358 doi:10.2214/ajr.162.6.8192008
- 359 14. Imanguli MM, Atkinson JC, Mitchell SA, et al. Salivary Gland Involvement in Chronic Graft-
360 Versus-Host Disease: Prevalence, Clinical Significance, and Recommendations for Evaluation.
361 *Biol Blood Marrow Transplant*. 2010;16(10):1362-1369. doi:10.1016/j.bbmt.2010.03.023
- 362 15. Dahllöf G, Wondimu B, Barr-Agholme M, Garming-Legert K, Remberger M, Ringdén O.
363 Xerostomia in children and adolescents after stem cell transplantation conditioned with total
364 body irradiation or busulfan. *Oral Oncol*. 2011;47(9):915-919.
365 doi:10.1016/j.oraloncology.2011.06.509
- 366 16. Pombo Lopes J, Rodrigues I, Machado V, Botelho J, Bandeira Lopes L. Chemotherapy and
367 Radiotherapy Long-Term Adverse Effects on Oral Health of Childhood Cancer Survivors: A
368 Systematic Review and Meta-Analysis. *Cancers*. 2023;16(1):110.
369 doi:10.3390/cancers16010110
- 370 17. Patni T, Lee C-T, Li Y, et al. Factors for poor oral health in long-term childhood cancer
371 survivors. *BMC Oral Health*. 2023;23(1):73. doi:10.1186/s12903-023-02762-0
- 372 18. Maes L, Vereecken C, Vanobbergen J, Honkala S. Tooth brushing and social characteristics of
373 families in 32 countries. *Int Dent J*. 2006;56(3):159-167. doi:[https://doi.org/10.1111/j.1875-](https://doi.org/10.1111/j.1875-595X.2006.tb00089.x)
374 [595X.2006.tb00089.x](https://doi.org/10.1111/j.1875-595X.2006.tb00089.x)

Dental health of CCS

- 375 19. Zaborskis A, Milciuviene S, Narbutaite J, Bendoraitiene E, Kavaliauskiene A. Caries
376 experience and oral health behaviour among 11 -13-year-olds: an ecological study of data from
377 27 European countries, Israel, Canada and USA. *Community Dent Health*. Jun 2010;27(2):102-
378 8.
- 379 20. Kuehni CE, Rueegg CS, Michel G, et al. Cohort Profile: The Swiss Childhood Cancer Survivor
380 Study. *Int J Epidemiol*. 2012;41(6):1553-1564. doi:10.1093/ije/dyr142
- 381 21. Michel G, von der Weid NX, Zwahlen M, Adam M, Rebholz C, Kuehni CE. The Swiss
382 Childhood Cancer Registry: rationale, organisation and results for the years 2001-2005. *Swiss*
383 *Med Wkly*. 2007;137(3536):502-509.
- 384 22. Statistik Bf. Bevölkerung nach Migrationsstatus [Population and migration status]. Accessed 17
385 April, 2024, <https://rb.gy/nf754k>
- 386 23. Statistik Bf. Bildungssystem [Education system]. Accessed 19 April, 2024,
387 [https://www.bfs.admin.ch/bfs/de/home/statistiken/bildung-
388 wissenschaft/bildungssystem.assetdetail.223674.html](https://www.bfs.admin.ch/bfs/de/home/statistiken/bildung-wissenschaft/bildungssystem.assetdetail.223674.html)
- 389 24. Steliarova Foucher E, Stiller C, Lacour B, Kaatsch P. International classification of childhood
390 cancer. *Cancer*. 2005;103(7):1457-1467.
- 391 25. Gianinazzi ME, Rueegg CS, Von Der Weid NX, Niggli FK, Kuehni CE, Michel G. Mental
392 health-care utilization in survivors of childhood cancer and siblings: the Swiss childhood cancer
393 survivor study. *Support Care Cancer*. 2014;22(2):339-349. doi:10.1007/s00520-013-1976-3
- 394 26. Van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate imputation by chained equations in
395 R. *Journal of Statistical Software*. 2011;45:1-67.
- 396 27. Carpenter JR, Bartlett JW, Morris TP, Wood AM, Quartagno M, Kenward MG. *Multiple*
397 *imputation and its application*. John Wiley & Sons; 2023.
- 398 28. Defabianis P, Bocca N, Romano F. Prevalence and association of dental anomalies and tooth
399 decay in Italian childhood cancer survivors. *J Clin Pediatr Dent*.
400 2023;doi:10.22514/jocpd.2023.056

Dental health of CCS

- 401 29. Halperson E, Matalon V, Goldstein G, et al. The prevalence of dental developmental anomalies
402 among childhood cancer survivors according to types of anticancer treatment. *Sci Rep*.
403 2022;12(1)doi:10.1038/s41598-022-08266-1
- 404 30. Kang C-M, Hahn SM, Kim HS, et al. Clinical Risk Factors Influencing Dental Developmental
405 Disturbances in Childhood Cancer Survivors. *Cancer Res Treat*. 2018;50(3):926-935.
406 doi:10.4143/crt.2017.296
- 407 31. Quispe RA, Rodrigues ACC, Buaes AMG, Capelozza ALA, Rubira CMF, Santos PSdS. A
408 case-control study of dental abnormalities and dental maturity in childhood cancer survivors.
409 *Oral Surg Oral Med Oral Radiol*. 2019/11/01/ 2019;128(5):498-507.e3.
410 doi:10.1016/j.oooo.2019.07.005
- 411 32. Moynihan P, Petersen PE. Diet, nutrition and the prevention of dental diseases. *Public Health*
412 *Nutr*. 2004;7(1a):201-226. doi:10.1079/phn2003589
- 413 33. Kumar S, Tadakamadla J, Johnson NW. Effect of Toothbrushing Frequency on Incidence and
414 Increment of Dental Caries:A Systematic Review and Meta-Analysis. *J Dent Res*.
415 2016;95(11):1230-1236. doi:10.1177/0022034516655315
- 416 34. Gawade PL, Hudson MM, Kaste SC, et al. A systematic review of dental late effects in
417 survivors of childhood cancer. *Pediatr Blood Cancer*. 2014;61(3):407-416.
418 doi:10.1002/pbc.24842
- 419 35. Martinsson U, Svärd A-M, Witt Nyström P, et al. Complications after proton radiotherapy in
420 children, focusing on severe late complications. A complete Swedish cohort 2008–2019. *Acta*
421 *Oncol*. 2023;62(10):1348-1356. doi:10.1080/0284186x.2023.2260946
- 422 36. Taylor CL, Price JM. The Tooth Hurts: Dental Health After Radiation Therapy for Head and
423 Neck Cancer. *Int J Radiat Oncol Biol Phys*. 2022;113(2):331-334.
424 doi:10.1016/j.ijrobp.2022.01.005
- 425 37. Grant SR, Grosshans DR, Bilton SD, et al. Proton versus conventional radiotherapy for
426 pediatric salivary gland tumors: Acute toxicity and dosimetric characteristics. *Radiother Oncol*.
427 2015;116(2):309-315. doi:10.1016/j.radonc.2015.07.022

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

Dental health of CCS

- 428 38. Dentistry AAoP. *Dental Management of Pediatric Patients Receiving Immunosuppressive*
429 *Therapy and/or Head and Neck Radiation. The Reference Manual of Pediatric Dentistry*. 2023.
430 39. Hong CH, daFonseca M. Considerations in the Pediatric Population with Cancer. *Dent Clin*
431 *North Am*. 2008;52(1):155-181. doi:10.1016/j.cden.2007.10.001

432

433 **Legends**

434 *Abbreviations*

435 CCS = childhood cancer survivors

436 HSCT = hematopoietic stem cell transplantation

437 ChCR = Swiss Childhood Cancer Registry

438 COG = Children's Oncology Group

439 ICC3 = International Classification of Childhood Cancer, third edition

440

441 *Figures*

442 **FIGURE 1** Prevalence of dental problems in childhood cancer survivors and siblings

443 *Please note: Only CCS reported gum problems during and after treatment. Percentages are based upon the number of*
444 *respondents for each dental problem reported in Table 2. For siblings, we report weighted percentages.*

445

446

447 **TABLE 1 Characteristics of childhood cancer survivors and siblings**

Socio-demographic characteristics	Survivors (N = 735)		Siblings (N = 144)	
	N	%	N	% ^a
<i>Age at study (mean, standard error)</i>	13.2 (0.1)		13.5 (0.3)	
<i>(median, IQR)</i>	12.8 [10.2– 15.4]		13.3 [11.1–15.5]	
<i>Age category</i>				
Children (5-15 years)	595	81%	90	77%
Adolescents (16-19 years)	140	19%	54	23%
<i>Sex</i>				
Girls	341	46%	71	50%
Boys	394	54%	73	50%
<i>Migration background</i>				
No	552	75%	118	76%
Yes	183	25%	26	24%
<i>Language</i>				
German	516	70%	105	69%
French	185	25%	33	26%
Italian	34	5%	6	4%
<i>Parental education</i>				
Primary education	45	6%	2	1%
Secondary education	242	33%	44	30%
Tertiary education	428	58%	98	68%
Missing	20	3%	0	0%
<i>Siblings</i>				
No	88	12%		
Yes	630	86%		
Missing	17	2%		
Cancer-related characteristics^d	N	%		
<i>ICCC3 main group</i>				
Leukemias	299	41%		
Lymphomas	60	8%		
CNS	123	17%		
Neuroblastoma	54	7%		
Retinoblastoma	29	4%		
Renal tumor	48	7%		
Hepatic tumor	6	1%		
Malignant bone tumors	17	2%		
Soft tissue sarcomas	52	7%		
Germ cell tumors	16	2%		
Other	5	1%		
Langerhans cell histiocytosis	26	4%		
<i>Age at diagnosis, mean (SD)</i>	4.9 (3.5)			
<i>median (IQR)</i>	4.2 [2.1 – 7.2]			
<i>Time since diagnosis, mean (SD)</i>	8.3 (1.9)			
<i>median (IQR)</i>	8.2 [6.9 – 9.4]			
<i>Year of diagnosis, mean (SD)</i>	2010 (3.2)			
<i>median (IQR)</i>	2010 [2005–2015]			
<i>Radiotherapy</i>	137	19%		
<i>Cranial radiotherapy</i>	68	9%		
<i>Chemotherapy</i>	588	80%		
<i>HSCT</i>	69	9%		
Autologous	30	4%		
Allogeneic	39	5%		
<i>Relapse</i>	81	11%		

448 ^a For siblings, the percentages are standardized to survivors based on sex, age at study, migration background, and
 449 language. The N is the original value. ^b Calculated based upon weighted t-test for continuous variables and weighted chi-
 450 square tests for categorical variables. ^c Not applicable since siblings were standardized based upon these variables to match
 451 the CCS. ^d No missing values for cancer-related characteristics.

452 ICCC3 = International Classification of Childhood Cancer, third edition; HSCT = hematopoietic stem cell transplantation

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

Dental health of CCS

453 **TABLE 2** Dental problems in childhood cancer survivors compared to siblings in
 454 multivariable logistic regressions

	Hypo- or microdontia (N = 875)				Enamel hypoplasia (N = 850)				Cavities or cavity-related tooth loss (N = 868)			
	OR	SE	95%CI	p	OR	SE	95%CI	p	OR	SE	95%CI	p
CCS (ref. sibling)	1.70	0.56	0.89;3.24	0.106	2.23	1.12	0.83;5.96	0.110	0.84	0.18	0.56;1.28	0.422
Age at study	0.94	0.03	0.87;1.01	0.079	0.95	0.04	0.88;1.03	0.248	0.98	0.03	0.92;1.04	0.498
Sex (ref. girls)	0.89	0.24	0.52;1.52	0.662	0.93	0.34	0.45;1.91	0.840	1.05	0.22	0.70;1.57	0.830

455 *Please note: We included all participants who provided full data for each of the respective outcomes, resulting in a*
 456 *different N for each model.*

457 *CCS = childhood cancer survivor*

458

459

Dental health of CCS

460 **TABLE 3** Cancer-related risk factors of dental problems in childhood cancer survivors in
 461 multivariable logistic regression

462

	Hypo- or microdontia (N = 725)				Enamel hypoplasia (N = 706)				Cavities or cavity-related tooth loss (N = 724)			
	OR	SE	95%CI	p	OR	SE	95%CI	p	OR	SE	95%CI	p
Cranial radiation (ref. no)	0.85	0.46	0.26;2.25	0.762	0.80	0.42	0.25;2.07	0.676	0.88	0.25	0.50;1.51	0.637
Chemotherapy (ref. no)	1.59	0.73	0.70;4.32	0.309	3.08	1.64	1.22;10.40	0.035	1.52	0.32	1.01;2.31	0.049
HSCT (ref. no)	5.37	1.91	2.64;10.69	<0.001	1.74	0.70	0.75;3.70	0.171	2.10	0.56	1.24;3.57	0.006
Age at diagnosis	0.85	0.04	0.76;0.94	0.002	0.92	0.04	0.83;1.00	0.069	1.04	0.02	0.99;1.09	0.094
Time since diagnosis	1.08	0.07	0.94;1.23	0.248	1.02	0.08	0.87;1.17	0.834	1.12	0.05	1.04;1.22	0.005
Relapse (ref. no)	1.11	0.48	0.45;2.49	0.814	2.23	0.86	1.01;4.63	0.038	0.62	0.17	0.35;1.05	0.082
	Gum problems during treatment (N = 676)				Gum problems after treatment (N = 637)							
	OR	SE	95%CI	p	OR	SE	95%CI	p				
Cranial radiation (ref. no)	1.52	0.45	0.84;2.72	0.163	1.46	0.52	0.70;2.87	0.287				
Chemotherapy (ref. no)	22.97	11.97	9.37;76.23	<0.001	4.62	2.21	1.98;13.49	0.001				
HSCT (ref. no)	2.03	0.59	1.16;3.60	0.014	1.65	0.57	0.82;3.18	0.147				
Age at diagnosis	1.11	0.03	1.06;1.18	<0.001	1.09	0.04	1.02;1.17	0.010				
Time since diagnosis	1.01	0.05	0.92;1.12	0.777	1.13	0.07	1.00;1.28	0.041				
Relapse (ref. no)	1.04	0.31	0.57;1.85	0.907	1.45	0.52	0.70;2.85	0.301				

463 *Please note: We included all participants who provided full data for each of the respective outcomes, resulting in a*
 464 *different N for each model.*

465 *HSCT = hematopoietic stem cell transplantation*

466

467

468

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

Dental health of CCS

469 **TABLE 4** Age-stratified analysis for cancer-related characteristics and dental problems in childhood
 470 cancer survivors

	< 5 years				=> 5 years			
	OR	SE	95%CI	p	OR	SE	95%CI	p
<i>Hypo-/microdontia</i>	N = 433				N = 298			
Cranial radiation (ref. no)	0.82	0.41	0.28;2.04	0.692	1.77	1.05	0.48;5.24	0.338
Chemotherapy (ref. no)	5.92	3.62	2.09;24.95	0.004	0.60	0.30	0.23;1.67	0.302
HSCT (ref. no)	2.88	1.02	1.41;5.74	0.003	1.82	1.23	0.40;6.17	0.378
Time since diagnosis	1.14	0.07	1.02;1.28	0.020	1.11	0.16	0.83;1.46	0.481
<i>Enamel hypoplasia</i>	N = 416				N = 290			
Cranial radiation (ref. no)	0.68	0.52	0.11;2.49	0.621	1.44	0.98	0.31;4.88	0.593
Chemotherapy (ref. no)	2.36	1.46	0.81;10.05	0.168	5.01	5.25	0.97;91.86	0.124
HSCT (ref. no)	2.32	1.08	0.87;5.55	0.070	1.65	1.14	0.35;5.73	0.466
Time since diagnosis	1.06	0.08	0.90;1.23	0.441	0.94	0.16	0.66;1.32	0.726
<i>Cavities or cavity-related tooth loss</i>	N = 428				N = 296			
Cranial radiation (ref. no)	0.40	0.18	0.15;0.94	0.046	1.20	0.44	0.58;2.45	0.609
Chemotherapy (ref. no)	1.42	0.43	0.79;2.64	0.252	1.73	0.51	0.98;3.15	0.065
HSCT (ref. no)	2.84	0.97	1.45;5.61	0.002	1.09	0.45	0.47;2.46	0.838
Time since diagnosis	1.22	0.06	1.11;1.35	<0.001	0.92	0.07	0.78;1.07	0.276

471 *Due to low cell count for relapse cases in those aged older than 5 years, we could not control for relapse in this these*
 472 *models.*

473 *HSCT = hematopoietic stem cell transplantation*

474

475

476

477

478

479

480

481

482

483

